Biolase (NASDAQ:BIOL) reported Q2 EPS of ($0.91), $0.27 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $10.63 million.
Biolase (NASDAQ:BIOL) reported Q2 EPS of ($0.91), $0.27 worse than the analyst estimate of ($0.64). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $10.63 million.